13 minutes ago
Results from the phase 3 trial were published in NEJM and simultaneously presented as a late-breaking abstract at AAD 2026.
58 minutes ago
Marston discusses his sub analysis of the VESALIUS-CV trial, which indicated reduced MACE risk in patients with diabetes and no atherosclerosis after evolocumab treatment.
1 hour ago
3 hours ago
3 hours ago
Rapid NGS and streamlined workflows are critical to delivering timely, actionable genomic insights in blood cancers, but access, reimbursement, and expertise gaps persist.